CINCINNATI—Refractive surgery firm LCA-Vision (Nasdaq: LCAV) said this week it will reduce the number of excimer lasers in its surgery centers from the present three machines to two as a cost-cutting measure.

The move—to begin this month, and projected to be fully implemented by the end of the third quarter—is expected to reduce operating costs by more than $3 million, a company announcement said.

LCA-Vision is using lasers made by Abbott Medical Optics (NYSE: ABT) and Alcon Laboratories (NYSE: ACL)in its centers. “We are capitalizing on an opportunity afforded by advancements in excimer laser platforms, which allow us to reduce the number of lasers per center and lower costs while ensuring our continued ability to achieve industry-leading clinical outcomes,” said Steven Straus, LCA-Vision’s chief executive officer.